Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Acitretin
Drug ID BADD_D00036
Description An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
Indications and Usage For the treatment of severe psoriasis in adults.
Marketing Status approved
ATC Code D05BB02
DrugBank ID DB00459
KEGG ID D02754
MeSH ID D017255
PubChem ID 5284513
TTD Drug ID D05QDC
NDC Product Code 17337-0003; 59981-011; 0093-1136; 0115-1752; 42291-087; 62147-0145; 0115-1751; 42794-081; 0378-7020; 71214-0698; 42291-088; 58159-058; 71052-692; 0115-1753; 17337-0004; 71214-0667; 0115-1750; 71214-0668; 71214-0669; 42291-086; 42794-080; 0093-1135; 0093-1138; 62147-0146; 76055-0001; 42794-083; 0378-7023
UNII LCH760E9T7
Synonyms Acitretin | Etretin | Isoacitretin | Isoetretin | Ro 10-1670 | Ro 101670 | Ro-10-1670 | Ro101670 | 13-cis-Acitretin | Neotigason | Soriatane | Acitretin, (Z,E,E,E)-Isomer | Ro-13-7652 | Ro137652 | Ro 13-7652 | Ro 137652
Chemical Information
Molecular Formula C21H26O3
CAS Registry Number 55079-83-9
SMILES CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Joint stiffness15.01.02.003--Not Available
Joint swelling15.01.02.0040.001250%Not Available
Kaposi's sarcoma16.33.02.001; 11.05.17.0010.001250%Not Available
Ketonuria20.02.01.009--Not Available
Laboratory test abnormal13.18.01.001--Not Available
Lacrimation disorder06.08.02.010--Not Available
Laryngitis22.07.03.001; 11.01.13.001--
Libido decreased19.08.03.001; 21.03.02.005--
Lip dry07.06.01.0030.003124%Not Available
Liver function test abnormal13.03.04.030--Not Available
Lymphocyte count decreased13.01.06.006--
Lymphocyte count increased13.01.06.007--
Macule23.03.03.0370.001250%Not Available
Malaise08.01.01.003--
Mass08.03.05.003--Not Available
Melaena07.12.02.004; 24.07.02.013--Not Available
Menopausal symptoms21.02.02.002--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Monocyte count decreased13.01.06.008--Not Available
Monocyte count increased13.01.06.009--Not Available
Mouth ulceration07.05.06.004--Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.0010.003374%
Myocardial infarction24.04.04.009; 02.02.02.007--
Myopathy15.05.05.001--Not Available
Nail disorder23.02.05.002--
Nasal dryness22.04.03.002--Not Available
Nausea07.01.07.001--
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene